Edit this page in Wiki Genes or see Wiki Gene.
Treatment of asthmatic patients with a cysteinyl leukotriene receptor-1 antagonist montelukast ( Singulair), decreases the eosinophil survival-enhancing activity produced by peripheral blood mononuclear leukocytes in vitro. Paper-9339252. Following stimulation the production of GM-CSF in monocytes was assessed. Paper-9339252.
GM-CSF was the predominant cytokine responsible for the eosinophil survival-enhancing activity (ESEA). Paper-9339252.
In another experiment PBMNC from 6 allergic patients were cultured in vitro in the presence of montelukast or vehicle. Paper-9339252.
CONCLUSION: Treatment of patients with montelukast decreased the production of MNC-derived cytokines, particularly GM-CSF. Paper-9339252.
METHODS: PBMNC obtained from 15 grass-allergic patients (7 treated with montelukast and 8 with a placebo) were cultured for 72 h. Paper-9339252.
BACKGROUND: Montelukast ( Singulair, MSD) has been shown to have a beneficial effect on the clinical symptoms of asthma. Paper-9339252.
In vitro production of GM-CSF by allergen-stimulated monocytes was significantly suppressed by addition of montelukast. Paper-9339252.
We suggest that cysteinyl leukotriene receptor-1 ( CysLT-R1) antagonists may act, at least partially, by diminishing the production of GM-CSF from PBMNCs. Paper-9339252.
We aimed to investigate the effect of montelukast treatment on the production of eosinophil survival-enhancing cytokines by peripheral blood mononuclear cells (PBMNC). Paper-9339252.
RESULTS: Eosinophil survival in the MNC supernatants from the placebo-treated patients was significantly (P < 0.05) higher than in supernatants from montelukast-treated patients. Paper-9339252.
Eosinophils from allergic patients were cultured with MNC supernatants alone or with addition of neutralizing antibodies, and the proportion of living cells was assessed by flow cytometry.
Important links !
iHOP - Information Hyperlinked over Proteins .
Concept & Implementation by Robert Hoffmann.